☆ 4.6 Article

Must Psilocybin Always “Assist Psychotherapy”?

AMERICAN JOURNAL OF PSYCHIATRY (2023)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life

Guy M. Goodwin et al.

Summary: This study explores the efficacy of COMP360, a synthetic formulation of psilocybin, in treating treatment-resistant depression (TRD). Results show that a single dose of psilocybin at 25 mg and 10 mg can significantly improve symptoms of depression. This study expands on previous research on the use of psilocybin in treating TRD.

JOURNAL OF AFFECTIVE DISORDERS (2023)

Add to Collection

Article Medicine, General & Internal

Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial

Robin von Rotz et al.

Summary: In this double-blind, randomized clinical trial, a single, moderate dose of psilocybin was found to significantly reduce depressive symptoms compared to a placebo condition for at least two weeks, with no serious adverse events recorded. Larger, multi-centric trials with longer follow-up periods are needed to further optimize this novel treatment paradigm.

ECLINICALMEDICINE (2023)

Add to Collection

Editorial Material Psychiatry

Studying Harms Is Key to Improving Psychedelic-Assisted Therapy-Participants Call for Changes to Research Landscape

Sarah McNamee et al.

Summary: This Viewpoint examines the potential for serious adverse events resulting from interactions between therapists and patients in trials of psychedelic-assisted therapy.

JAMA PSYCHIATRY (2023)

Add to Collection

Article Clinical Neurology

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up

Natalie Gukasyan et al.

Summary: This study demonstrates that psilocybin-assisted therapy can have long-lasting antidepressant effects in patients with moderate to severe depression, as observed over a 12-month period.

JOURNAL OF PSYCHOPHARMACOLOGY (2022)

Add to Collection

Article Clinical Neurology

Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals

Drummond E-Wen McCulloch et al.

Summary: This study evaluated the long-term effects of psilocybin on resting-state functional connectivity in healthy psychedelic-naive volunteers. The results showed that psilocybin decreased executive control network connectivity at 1 week, which predicted increased mindfulness at 3 months. This suggests that psilocybin may have lasting effects on brain connectivity and mindfulness.

JOURNAL OF PSYCHOPHARMACOLOGY (2022)

Add to Collection

Article Pharmacology & Pharmacy

Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression

Roberta Murphy et al.

Summary: This study investigated the relationship between therapeutic alliance and treatment outcomes, finding that the strength of therapeutic alliance influenced the effectiveness of depression treatment, especially in psychedelic-assisted therapy, where emotional breakthrough and mystical experiences also played a role in treatment outcomes.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Article Psychiatry

A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial

Rebecca B. Price et al.

AMERICAN JOURNAL OF PSYCHIATRY (2022)

Add to Collection

Article Medicine, General & Internal

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression

Guy M. Goodwin et al.

Summary: Psilocybin may be effective in treating treatment-resistant depression, but dosage and adverse effects need further investigation.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Psychiatry

Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder A Randomized Clinical Trial

Michael P. Bogenschutz et al.

Summary: This study aimed to evaluate the effects of high-dose psilocybin on patients with AUD. The results showed that psilocybin combined with psychotherapy significantly decreased the percentage of heavy drinking days.

JAMA PSYCHIATRY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain

Nakul Ravi Raval et al.

Summary: This study showed that a single dose of psilocybin can lead to increased SV2A density and decreased 5-HT2AR density in the pig brain, suggesting a potential role in the antidepressant effects of psilocybin.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Neurosciences

Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine

Danilo De Gregorio et al.

Summary: A resurgence of interest in hallucinogens for the treatment of psychiatric disorders has emerged, with studies confirming the efficacy of ketamine in treating depression. Emerging evidence also suggests potential therapeutic properties of psilocybin, LSD, and MDMA for mental diseases.

JOURNAL OF NEUROSCIENCE (2021)

Add to Collection

Article Psychiatry

Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical Research

Sara J. Tai et al.

Summary: This paper describes the development and practical implementation of a therapist training program of psychological support within a current phase IIb international, multicenter, randomized controlled study of psilocybin therapy for treatment-resistant depression. The program consists of online learning, in-person training, applied clinical training, and ongoing individual mentoring. Feedback from therapists trained in the program indicated that the didactic and experiential learning helped build their conceptual understanding and skill development in the therapeutic approach.

FRONTIERS IN PSYCHIATRY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study

Jennifer M. Mitchell et al.

Summary: The results demonstrate that MDMA-assisted therapy is safe and effective in treating severe post-traumatic stress disorder. Compared with placebo, MDMA significantly reduces CAPS-5 scores and improves functional impairment.

NATURE MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Trial of Psilocybin versus Escitalopram for Depression

Robin Carhart-Harris et al.

Summary: The study compared the efficacy of psilocybin and escitalopram in treating patients with major depressive disorder. While there was no significant difference in antidepressant effects between the two drugs at week 6, secondary outcomes generally favored psilocybin over escitalopram, though these results were not adjusted for multiple comparisons. Larger and longer trials are needed to further compare psilocybin with established antidepressants.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Psychiatry

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder A Randomized Clinical Trial

Alan K. Davis et al.

Summary: The study showed that psilocybin therapy with psychological support is effective in treating MDD, building on previous findings in patients with cancer and depression, as well as in a nonrandomized study in patients with treatment-resistant depression.

JAMA PSYCHIATRY (2021)

Add to Collection

Article Neurosciences

Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo

Ling-Xiao Shao et al.

Summary: The study showed that psilocybin can induce rapid and lasting synaptic rewiring in the cortex, increasing spine size and density. This structural change may have potential implications for long-term integration of experiences and lasting beneficial actions.

NEURON (2021)

Add to Collection

Review Psychiatry

Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics

Cato M. H. de Vos et al.

Summary: Clinical studies suggest that psychedelics induce rapid changes in neuroplasticity mechanisms, leading to alterations in gene and protein expression, increased neurotrophic factor levels, and enhanced dendritic complexity. Repeated administration of psychedelics can directly stimulate neurogenesis and elevate BDNF mRNA levels, indicating potential long-lasting effects on brain plasticity. Future research could focus on deciphering specific cellular mechanisms activated by different psychedelics to better understand their therapeutic potential.

FRONTIERS IN PSYCHIATRY (2021)

Add to Collection

Article Neurosciences

Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects

Friederike Holze et al.

NEUROPSYCHOPHARMACOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Emotions and brain function are altered up to one month after a single high dose of psilocybin

Frederick S. Barrett et al.

SCIENTIFIC REPORTS (2020)

Add to Collection

Review Psychology, Clinical

The use of the psychological flexibility model to support psychedelic assisted therapy

Rosalind Watts et al.

JOURNAL OF CONTEXTUAL BEHAVIORAL SCIENCE (2020)

Add to Collection

Article Neurosciences

Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels

Martin K. Madsen et al.

NEUROPSYCHOPHARMACOLOGY (2019)

Add to Collection

Article Clinical Neurology

Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory

Leor Roseman et al.

JOURNAL OF PSYCHOPHARMACOLOGY (2019)

Add to Collection

Review Psychiatry

Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline

Allison A. Feduccia et al.

FRONTIERS IN PSYCHIATRY (2019)

Add to Collection

Article Neurosciences

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up

R. L. Carhart-Harris et al.

PSYCHOPHARMACOLOGY (2018)

Add to Collection

Article Cell Biology

Psychedelics Promote Structural and Functional Neural Plasticity

Calvin Ly et al.

CELL REPORTS (2018)

Add to Collection

Article Psychology, Clinical

Long-term follow-up of psilocybin-facilitated smoking cessation

Matthew W. Johnson et al.

AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE (2017)

Add to Collection

Article Psychology, Multidisciplinary

Development of a Psychotherapeutic Model for Psilocybin-Assisted Treatment of Alcoholism

Michael P. Bogenschutz et al.

JOURNAL OF HUMANISTIC PSYCHOLOGY (2017)

Add to Collection

Editorial Material Clinical Neurology

Psilocybin: Psychotherapy or drug?

Guy M. Goodwin

JOURNAL OF PSYCHOPHARMACOLOGY (2016)

Add to Collection

Article Clinical Neurology

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

Roland R. Griffiths et al.

JOURNAL OF PSYCHOPHARMACOLOGY (2016)

Add to Collection

Article Psychiatry

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

Robin L. Carhart-Harris et al.

LANCET PSYCHIATRY (2016)

Add to Collection

Article Psychiatry

Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer

Charles S. Grob et al.

ARCHIVES OF GENERAL PSYCHIATRY (2011)

Add to Collection

Article Psychology, Clinical

Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder

Francisco A. Moreno et al.

JOURNAL OF CLINICAL PSYCHIATRY (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.